- Home
- WOOF vs KALV Comparison
WOOF vs KALV Comparison
Compare WOOF & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WOOF
- KALV
- Stock Information
- Founded
- WOOF 1965
- KALV N/A
- Country
- WOOF United States
- KALV United States
- Employees
- WOOF N/A
- KALV N/A
- Industry
- WOOF Other Specialty Stores
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- WOOF Consumer Discretionary
- KALV Health Care
- Exchange
- WOOF Nasdaq
- KALV Nasdaq
- Market Cap
- WOOF 937.4M
- KALV 796.4M
- IPO Year
- WOOF 2021
- KALV N/A
- Fundamental
- Price
- WOOF $3.46
- KALV $14.01
- Analyst Decision
- WOOF Hold
- KALV Strong Buy
- Analyst Count
- WOOF 11
- KALV 8
- Target Price
- WOOF $3.91
- KALV $26.43
- AVG Volume (30 Days)
- WOOF 4.7M
- KALV 1.0M
- Earning Date
- WOOF 08-28-2025
- KALV 09-11-2025
- Dividend Yield
- WOOF N/A
- KALV N/A
- EPS Growth
- WOOF N/A
- KALV N/A
- EPS
- WOOF N/A
- KALV N/A
- Revenue
- WOOF $6,045,495,000.00
- KALV $1,426,000.00
- Revenue This Year
- WOOF $0.03
- KALV N/A
- Revenue Next Year
- WOOF $1.36
- KALV $221.95
- P/E Ratio
- WOOF N/A
- KALV N/A
- Revenue Growth
- WOOF N/A
- KALV N/A
- 52 Week Low
- WOOF $2.28
- KALV $7.30
- 52 Week High
- WOOF $6.29
- KALV $17.28
- Technical
- Relative Strength Index (RSI)
- WOOF 50.32
- KALV 48.69
- Support Level
- WOOF $3.57
- KALV $13.26
- Resistance Level
- WOOF $4.19
- KALV $17.28
- Average True Range (ATR)
- WOOF 0.23
- KALV 1.00
- MACD
- WOOF 0.00
- KALV 0.08
- Stochastic Oscillator
- WOOF 32.41
- KALV 25.34
About WOOF Petco Health and Wellness Company Inc.
Petco Health and Wellness Co Inc is a pet specialty retailer focused on improving the lives of pets, pet parents, and its own partners with pet care centers in approximately 50 states, the District of Columbia and Puerto Rico. The Company also offers an expanded range of consumables, supplies, and services through its website and mobile app.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.